DNLI News and Press, Denali Therapeutics Inc. From 11/29/23

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics PR Newswire Quotient's Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body's trilli...

2023-11-15 01:56:28 ET Summary Baillie Gifford's 13F portfolio value decreased from ~$118B to ~$110B this quarter. The top three holdings in the portfolio are MercadoLibre, NVIDIA, and Tesla. There were stake increases in companies such as PDD Holdings, Coupang, and BeiGene, a...

2023-11-07 17:20:20 ET More on Denali Therapeutics Denali's New Summit: Changing Hunter Syndrome Landscape Seeking Alpha’s Quant Rating on Denali Therapeutics Historical earnings data for Denali Therapeutics Financial information for Denali Therapeutic...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal st...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Denali Therapeutics Inc. (DNLI) is expected to report $-0.83 for Q3 2023

Flagship Pioneering Launches Pioneering Intelligence PR Newswire CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to accelerate...

2023-10-26 09:49:41 ET Summary INmune Bio is a phase 2 stage biotech company focusing on Alzheimer's and other diseases with its lead asset, XPro, and its endogenous NK cell activator, INKmune. INmune's XPro has shown promising results in stabilizing Alzheimer's disease and improv...